Patents by Inventor Carl Scandella

Carl Scandella has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for purifying authentic IGF from yeast hosts
    Patent number: 7193042
    Abstract: Methods for purifying authentic, properly folded IGF polypeptides from yeast transformants are disclosed. The methods include a refolding step and provide for high yields of authentic IGF from a variety of yeast strains.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: March 20, 2007
    Assignees: Chiron Corporation, Cephalon, Inc.
    Inventors: Cynthia Cowgill, Luis Juarbe-Osorio, Patricio Riquelme, Glenn Dorin, Christopher M. Bussineau, Robert D. Kudrna, Carl Scandella, Russell A. Brierley, Joan N. Abrams, John M. Hanson, Francis C. Maslanka
  • Methods of purifying authentic IGF from yeast hosts
    Patent number: 7071313
    Abstract: Methods for purifying authentic, properly folded IGF polypeptides from yeast transformants are disclosed. The methods include a refolding step and provide for high yields of authentic IGF from a variety of yeast strains.
    Type: Grant
    Filed: May 2, 2000
    Date of Patent: July 4, 2006
    Assignees: Cephalon, Inc., Chiron Corporation
    Inventors: Cynthia Cowgill, Luis Juarbe-Osorio, Patricio Riquelme, Glenn Dorin, Christopher M. Bussineau, Robert D Kudrna, Asuman G. Ozturk, Carl Scandella, Russell A. Brierley, Joan N. Abrams, John M. Hanson, Francis C. Maslanka
  • Purified GP120 composition retaining natural conformation
    Patent number: 5696238
    Abstract: A method for purifying recombinant HIV gp120 so as to provide a glycopeptide having protein/protein binding properties substantially identical to natural viral HIV gp120, which comprises fractionating a composition containing crude gp120 sequentially using (1) ion exchange chromatography, (2) hydrophobic-interaction chromatography, and (3) size exclusion filtration, collecting at each step a fraction that exhibits specific binding affinity for CD4 peptide. The process is carried out in the absence of any affinity purification steps or any steps (such as reverse-phase HPLC) that use contact protein with organic solvents. The product obtained by this method is a purified, full-length, non-fusion recombinant HIV gp120 glycoprotein having protein/protein interaction properties substantially identical to gp120 as presented on an HIV virus, including binding affinity for CD4 and binding affinity for at least one antibody capable of neutralizing HIV infectivity.
    Type: Grant
    Filed: May 11, 1995
    Date of Patent: December 9, 1997
    Assignee: Chiron Corporation
    Inventors: Nancy L. Haigwood, Carl Scandella
  • Purified gp120 composition retaining natural conformation
    Patent number: 5653985
    Abstract: A method for purifying recombinant HIV gp120 so as to provide a glycopeptide having protein/protein binding properties substantially identical to natural viral HIV gp120, which comprises fractionating a composition containing crude gp120 sequentially using (1) ion exchange chromatography, (2) hydrophobic-interaction chromatography, and (3) size exclusion filtration, collecting at each step a fraction that exhibits specific binding affinity for CD4 peptide. The process is carried out in the absence of any affinity purification steps or any steps (such as reverse-phase HPLC) that use contact protein with organic solvents. The product obtained by this method is a purified, full-length, non-fusion recombinant HIV gp120 glycoprotein having protein/protein-interaction properties substantially identical to gp120 as presented on an HIV virus, including binding affinity for CD4 and binding affinity for at least one antibody capable of neutralizing HIV infectivity.
    Type: Grant
    Filed: May 11, 1995
    Date of Patent: August 5, 1997
    Assignee: Chiron Corporation
    Inventors: Nancy L. Haigwood, Carl Scandella
  • Purified gp120 compositions retaining natural conformation
    Patent number: 5614612
    Abstract: A method for purifying recombinant HIV gp120 so as to provide a glycopeptide having protein/protein binding properties substantially identical to natural viral HIV gp120, which comprises fractionating a composition containing crude gp120 sequentially using (1) ion exchange chromatography, (2) hydrophobic-interaction chromatography, and (3) size exclusion filtration, collecting at each step a fraction that exhibits specific binding affinity for CD4 peptide. The process is carried out in the absence of any affinity purification steps or any steps (such as reverse-phase HPLC) that use contact protein with organic solvents. The product obtained by this method is a purified, full-length, non-fusion recombinant HIV gp120 glycoprotein having protein/protein-interaction properties substantially identical to gp120 as presented on an HIV virus, including binding affinity for CD4 and binding affinity for at least one antibody capable of neutralizing HIV infectivity.
    Type: Grant
    Filed: May 9, 1994
    Date of Patent: March 25, 1997
    Inventors: Nancy L. Haigwood, Carl Scandella